India is likely to see the Oxford-AstraZeneca vaccine being approved for emergency use in next few days as the updated data submitted by Serum Institute of India (SII) appears “satisfactory”, top government sources said. Once evaluation of data is complete, the regulator may not wait for the vaccine to get approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA). “We can take our regulatory decisions independently. The company has submitted the same data here from clinical trials in the UK and Brazil and rolling reviews are going on. The updated information shared by Serum Institute also appears satisfactory. We are hopeful that based on regulatory assessment, the vaccine will be approved in a day or two,” a senior official told TOI. However, it is quite possible that the UK may also meanwhile grant the emergency use authorisation as MHRA is already reviewing the data for the vaccine developed by Oxford University and pharma major AstraZeneca. A PTI report said the drug major's CEO Pascal Soriot has reported the Covishield vaccine to have achieved a “winning formula” for efficacy. Soriot’s comments were carried in an interview with the Sunday Times newspaper. He added that he believes trials will show his firm has achieved a vaccine efficacy equal to Pfizer-BioNTech at 95% and Moderna at 94.5 per cent. “We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else,” the chief executive said, while only adding that data would be published at “some point”. He also said that the vaccine “should be” effective against the new highly transmissible variant of the coronavirus.